Crossmark

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus CEAM (Lomustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen before Autologous Haematopoietic Cell Transplantation for Lymphoma Patients

Crossref DOI link: https://doi.org/10.1007/s12288-025-02122-8

Published Online: 2025-08-14

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mehdizadeh, Mahshid

Tavakoli, Farzaneh

Farjami, Mohammad

Javani, Fatemeh

Parkhideh, Sahar

Parkhideh, Sayeh

Hajifathali, Abbas
License Information

Text and Data Mining valid from 2025-08-14

Version of Record valid from 2025-08-14
More Information

Article History

Received: 4 April 2025

Accepted: 30 July 2025

First Online: 14 August 2025

Declarations

:

: Sahar and Sayeh Parkhideh are sisters and both work as assistant and associate professor of oncology, respectively in Hematopoietic Stem Cell Research Center.

Document is current

Any future updates will be listed below